INTERNATIONAL WORKSHOP ON
NASH BIOMARKERS
WASHINGTON DC, USA • 5-6 MAY 2017

WHO SHOULD ATTEND?
Clinical, basic and translational researchers from academia and industry, physicians, pharmacologists, drug development experts, government representatives, young investigators and other experts involved in biomarker- and drug development for NASH

VENUE
Washington Marriott Georgetown
1221 22nd Street NW
Washington, District Of Columbia
20037, USA

WHY SHOULD YOU ATTEND?
This independent workshop will provide a high quality platform for presentation of the latest research results in the field of biomarkers for NASH.

It provides an interactive forum to experts for in-depth discussion and debate in order to reach consensus and develop strategies.

The program gathers experts from all relevant disciplines in order to integrate efforts and advance this important field of research.

Discounted registration fees apply to government employees (FDA, NIH)

ORGANIZING COMMITTEE
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom

Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France

Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, the Netherlands

Roberto Calle, MD
Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA

Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, United States

Christopher Leptak, MD, PhD
FDA Office of New Drugs, Silver Spring, MD, USA

Veronica Miller, PhD
The Liver Forum, Washington, DC, USA

Arun Sanyal, MD, MBBS
Virginia Commonwealth University, Richmond, VA, USA

Elmer Schabel, MD
European Medicines Agency, London, UK & BfArM, Bonn, Germany

Claude Sirlin, MD
UC San Diego, San Diego, CA, USA

Meeting Partners

Registration and information: www.expertmedicalevents.com
Submit your data for this workshop

We invite you to submit abstracts for a poster or oral presentation on the following topics:

- Innovations in Design and Analysis
- Markers of Disease Activity
- Markers of Disease Stage
- Novel technologies in NASH biomarker development

**MEETING OBJECTIVES**

- Review the current regulatory landscape and gaps in regulatory science related to biomarker development for NAFLD
- Review the gaps in evidence needed to qualify specific biomarkers for NAFLD
- Stimulate collaborative science to accelerate biomarker development for NAFLD
- Promote innovation in design and analytic approaches to biomarker development for NAFLD